Among the several players and pathways involved in lipid dysmetabolism in CHC, one of the key mechanisms that appears to induce hepatic steatosis development is the inhibition of peroxisomal proliferator activated receptor α (PPAR-α) [13,14]. This evidence concerns the gene PPARA and fatty liver disease.